Yearly and Twice Yearly Pharmacotherapy in Postmenopausal Osteoporosis.

The article discusses the importance of yearly and twice yearly pharmacology in treating postmenopausal osteoporosis. It examines the efficacy of Zoledronic acid and Denosumab in treating this osteoporosis. It notes that 5 milligram of intravenous infusion of Zoledronic acid can lower bone turnover markers and vertebral marker rate, while the Denosumab can improve bone mineral density and reduce bone resorption in postmenopausal women having low bone mass. Moreover, it explores the adverse effects of these drugs.